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Theaimofthisstudywastoevaluatetheimpactoffolicaciduseinpregnancyforthereductionofneuraltubedefects(NTDs)inthe
northwest region of Iran. We studied 243 women with pregnancies complicated by some forms of birth defect(s). These patients
were identiﬁed by medical diagnostic tests as having a fetus with some types of congenital anomalies. The prevalence of NTDs
among pregnant women who were referred for therapeutic termination of pregnancy was 24.7 percent. Consumption of folic acid
prevented NTDs by 79 percent (Odds Ratio = 0.21,CI 95%:0.12–0.40) and 94 percent (Odds Ratio = 0.06,CI 95%:0.03–0.15)
compared to pregnancies complicated by other anomalies and normal pregnancies, respectively. Hydrops fetalis, hydrocephaly,
Down syndrome, and limb anomalies did not have any signiﬁcant association with the folic acid use. Along with the advice for
the consumption of folic acid for pregnant women, they should be oﬀered prenatal screening or diagnostic tests to identify fetal
abnormalities for possible termination of pregnancy.
1.Introduction
Atleastonecongenitalanomalyispresentinbetween1%and
6%ofallinfantsthroughouttheworld[1].Ofallthepossible
birth defects, public health authorities are particularly
concerned with congenital anomalies known as neural tube
defects (NTDs) because they are preventable. NTDs are one
of the most common birth defects in many regions [2, 3].
NTDs are now preventable with adequate intake of folic
acid prior to conception and during pregnancy, which has
been shown to decrease the likelihood of a child being born
with a defect [4, 5].
Weinvestigatedwhetherpreconceptionaluseoffolicacid
was associated with a reduced risk for delivering oﬀspring
with NTDs.
2. Methods
All pregnant women in the area are routinely examined by
specialist physicians (i.e., gynecologists and obstetricians)
for maternity care or possible intervention and treatment
if necessary. The researchers studied 243 women with
pregnancies complicated by some forms of birth defect(s)
in the population under the Tabriz Registry of Congenital
Anomalies (TRoCA) program. TRoCA is an established
registry of birth defects covering an annual average of 20000
births in the northwest of Iran [6].
The patients were identiﬁed by medical diagnostic tests
as having a fetus with some types of congenital anomalies.
The patients were then referred to at least three consultant
specialists for ﬁnal conﬁrmation of congenital anomalies.
Following this, they were then oﬀered termination of preg-
nancy according to the current national guideline for the
termination of pregnancy.
Study subjects included all women referred to the clinical
examination at Legal Medicine Organization (LMO) in the
northwest of Iran. In Iran, it is obligatory to get permission
for therapeutic abortion if a pregnancy is diagnosed as hav-
ing a fetus with a major congenital anomaly. This permission
is issued by LMO for eligible women. The use of folic acid
and type of birth defect(s) was evaluated in those women.2 Journal of Pregnancy
Table 1: Folic acid and type of anomaly.
Type of anomaly Used Did not use
n % (CI 95%) n % (CI 95%)
Neural Tube Defects (NTDs) 28 16.09 (11.31–22.15) 32 47.06 (35.67–58.76)
Hydrops fetalis 20 11.49 (7.52–16.99) 6 8.82 (4.11–17.94)
Hydrocephaly 26 14.94 (10.35–20.88) 8 11.74 (6.08–21.53)
Down syndrome 16 9.19 (5.71–14.33) 5 7.35 (3.18–16.09)
Limb anomalies 20 11.49 (7.52–16.99) 2 2.94 (0.81–10.1)
Others 65 36.78 (30.33–44.51) 15 22.05 (13.85–33.26)
We compared two groups.
Group I: 175 women who had used folic acid on a
daily-based dose of 400 microgram until the end of
their ﬁrst trimester of pregnancy.
GroupII:68womenwhoneverusedfolicacidduring
their pregnancies.
Agroupofwomen(n = 118)withnormalpregnancywas
also taken to assess the current situation of folic acid use in
general population of pregnant women.
3. Results
Themeanageofmotherswas28.6years(range:14–44years).
The majority of them (65%) had lower socioeconomic status
(education and occupation).
T h ep r e v a l e n c er a t eo fN T D sa m o n gp r e g n a n tw o m e n
who were referred for therapeutic termination of pregnancy
was 24.7 percent. The occurrence of NTDs was 16.1 percent
(CI 95%: 11.31–22.15) and 47.1 percent (CI 95%: 35.67–
58.76) in group I and II, respectively.
ConsumptionoffolicacidpreventedNTDsby79percent
(Odds Ratio = 0.21, CI 95%: 0.12–0.40) and 94 percent
(Odds Ratio = 0.06, CI 95%: 0.03–0.15) compared to
pregnancies complicated by other anomalies and normal
pregnancies, respectively.
Other anomalies including hydrops fetalis, hydrocephaly,
Down syndrome, and limb anomalies did not have any
signiﬁcantassociationwiththeuseoffolicacidbefore/during
the pregnancy (Table 1).
We found that 93 percent of the general population of
pregnant women with normal pregnancy take folic acid on a
regular basis.
4. Discussion
We investigated the association between folic acid use and
occurrence of NTDs in a group of women referred for
therapeuticterminationofpregnancy.Theﬁndingsindicated
thatfolicacidusebeforeandafterconceptionmayhavearole
to reduce the rate of NTDs in the region.
Previous studies showed a prevalence rate of 7.03 (per
10,000 births in general population) for NTDs in the same
area [1, 7]. We recognized/identiﬁed 60 of them in this study
that referred for the termination of pregnancy because of
NTDs.
Folic acid use is a routing practice in Iranian Public
Health System. Ninety-three percent reported the use of
folic acid in the general population of pregnant women
with normal pregnancy. The same ﬁgure in women with
a pregnancy complicated by a birth defect was 72 percent
with an irregular use. Postma et al. reported that 49.4%
of pregnant women had used folic acid to prevent fetal
anomaliesbeforepregnancy[8],whereasonly2%ofMexican
pregnant women had received folic acid before pregnancy. A
Cochrane Collaboration systematic review reported on the
eﬀects of increased folic acid intake through supplementa-
tionorincreasedconsumptioninthedietonNTDsandother
congenitalanomalieswhentakenpericonceptionally,deﬁned
as prior to and during the ﬁrst two months of pregnancy.
The study population of interest was women planning to
become pregnant regardless of whether they had a previous
pregnancy with NTDs [9].
Ourﬁndingsshowedthatinourregionofstudyfolicacid
consumption by all pregnant women would reduce NTDs
by 79 percent. This is consistent with the MRC randomized
controlled trial with a reduction rate of 72 percent [10].
The results may emphasize again the necessity of folic acid
fortiﬁcation of grain. The ﬂour fortiﬁcation with folic acid
wasinitiatedinIrantwodecadesago.However,itisstillbeing
performed as a pilot programme by the ministry of health
and no formal results on the outcome have been reported yet
for the whole country [11].
There were several limitations in our study: one of them
was that the duration of folic acid supplementation use
diﬀered between women. The second limitation was that
there was no distinction between multivitamins intended
for general consumption and intended speciﬁcally for use as
prenatal supplements for the prevention of birth defect(s).
5. Conclusion
Women in the reproductive age group should be advised
about the beneﬁts of folic acid supplementation during
maternal health care visits (i.e., family planning, etc.). Along
with the advice of the consumption of folic acid for pregnant
women, they should also be oﬀered prenatal screening or
diagnostic tests to identify fetal abnormalities for possible
termination of pregnancy. Those tests are routinely available
in public and private health care sections in the country.
Since we were unable to evaluate the cost eﬀectiveness
of NTDs prevention program with folic acid, more studiesJournal of Pregnancy 3
are needed to assess the costs of treatment and health care
services for NTD patients and the cost eﬀectiveness of the
national folic acid supplementation programs and policies.
Further investigations are also recommended to investigate
the etiology of NTD in the area.
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